Abstract
DTC is considered the most common endocrine neoplasm, and 131I therapy has been proven to be an important component in the management strategy. Currently, most research focuses on the adverse effects of radiation exposure to 131I therapy. Some results, based on large-scale and long-term inves- tigation, show new information. Although 131I therapies are usually well tolerated, clinicians involved in the management of DTC need to be aware of the potential toxicity of 131I and take all measures to reduce these effects to a minimum. The aim of this review is to present the adverse effects of 131I therapy for DTC. Key words: Thyroid neoplasms ; Radiotherapy; Iodine radioisotopes ; Adverse effects
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Chinese Journal of Nuclear Medicine and Molecular Imaging
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
